Citius Oncology (NASDAQ:CTOR) Issues Quarterly Earnings Results

Citius Oncology (NASDAQ:CTOR) issued its quarterly earnings data on Friday. The company reported ($0.27) EPS for the quarter, missing the consensus estimate of ($0.01) by ($0.26), FiscalAI reports. The business had revenue of $1.67 million for the quarter, compared to analyst estimates of $7.00 million.

Citius Oncology Stock Performance

NASDAQ CTOR traded down $0.02 on Friday, reaching $0.96. 25,246 shares of the stock were exchanged, compared to its average volume of 230,932. The firm has a market capitalization of $85.04 million, a PE ratio of -3.11 and a beta of 3.56. The company has a current ratio of 0.83, a quick ratio of 0.32 and a debt-to-equity ratio of 0.07. Citius Oncology has a one year low of $0.49 and a one year high of $6.19. The company’s 50-day simple moving average is $0.81 and its two-hundred day simple moving average is $1.07.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Bank of America Corp DE raised its holdings in Citius Oncology by 5,256.9% in the second quarter. Bank of America Corp DE now owns 8,571 shares of the company’s stock worth $37,000 after purchasing an additional 8,411 shares in the last quarter. Citadel Advisors LLC purchased a new position in shares of Citius Oncology during the 3rd quarter valued at approximately $36,000. Geode Capital Management LLC lifted its position in shares of Citius Oncology by 179.0% during the 2nd quarter. Geode Capital Management LLC now owns 57,297 shares of the company’s stock valued at $249,000 after buying an additional 36,758 shares in the last quarter. OMERS ADMINISTRATION Corp acquired a new position in Citius Oncology in the 4th quarter valued at $104,000. Finally, Jane Street Group LLC acquired a new position in Citius Oncology in the 2nd quarter valued at $465,000. 70.52% of the stock is owned by hedge funds and other institutional investors.

About Citius Oncology

Citius Oncology, Inc is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.